Research and Scholarship
Impact of Adherence to Ibrutinib on Clinical Outcomes in Real-World Patients With Chronic Lymphocytic Leukemia
Lauren M. Garner, PharmD, BCPPS, Theresa Kline, PharmD, BCPS, BCCP, Jordan Miller, PharmD, BCOP, CPP, Allison Deal, MS, Anqi Zhu, MS, PhD(c), Margaret R. Sketch, PharmD, MPH, Catherine C. Coombs, MD, and Benyam Muluneh, PharmD, BCOP, CPP
From University of North Carolina Medical Center, Chapel Hill, North Carolina
Authors’ disclosures of conflicts of interest are found at the end of this article.
Correspondence to: Lauren M. Garner, PharmD, BCPPS, 101 Manning Drive, Chapel Hill, NC 27517. E-mail: firstname.lastname@example.org
J Adv Pract Oncol 2021;12(1):20–28 |
© 2021 Harborside™
Background: Chronic lymphocytic leukemia (CLL) is a B-cell neoplasm with clonal expansion of small lymphocytes. Ibrutinib, an irreversible inhibitor of Bruton tyrosine kinase (BTK), is a first-line treatment option, and recent data suggest that strict adherence is directly related to clinical outcomes. Objectives: The primary objective of this study was to quantify ibrutinib adherence rates in real-world patients with CLL on ibrutinib; secondary outcomes included progression-free survival and overall survival. Methods: This retrospective study included subjects who were treated at a large academic medical center over approximately 5 years. Subjects were at least 18 years, diagnosed with CLL or small lymphocytic lymphoma, and treated with ibrutinib monotherapy for at least 6 months. Adherence was quantified using the medication possession ratio (MPR), which is the ratio of the sum of days’ supply of medication in a period over the number of days in that period, and was based on fill history from the medical center’s specialty pharmacy. Results: For the 32 subjects in this study, the mean ibrutinib adherence rate was 91.7% (range, 84.4%–100%). Only 3 subjects had disease progression, and 1 death was recorded while on therapy (all with MPR < 95%); therefore, analyses of clinical outcomes were unable to be assessed due to a low number of events. There were no statistically significant differences in rates of adherence based on baseline characteristics and adverse drug events. Conclusion: In patients with CLL treated with ibrutinib, mean adherence was 91.7%, which is lower than rates seen in clinical trials.
For access to the full length article, please sign in